Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

437.15 +2.63 (+0.61%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
68 69 Next >
News headline image
3 Stocks to Buy and Hold Forever ↗
These stocks are built for the long run. 
Via The Motley Fool
News headline image
Prediction: These 3 Phenomenal Stocks Are Set to Soar ↗
These stocks are already solid winners in 2024. They should be able to keep the momentum going. 
Via The Motley Fool
News headline image
Time To Invest And Or Trade In Bio-Tech Stocks? ↗
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
News headline image
Biotech Breakout: Stocks for Your Watchlist
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. 
Via MarketBeat
Topics ETFs
News headline image
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years ↗
 
Via Benzinga
News headline image
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know ↗
 
Via Benzinga
News headline image
Looking Into Vertex Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals ↗
 
Via Benzinga
News headline image
3 No-Brainer Stocks to Buy in September ↗
There's at least one key common denominator here: tremendous growth prospects. 
Via The Motley Fool
News headline image
3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever ↗
These three have secure core businesses, plus multiple paths to grow. 
Via The Motley Fool
News headline image
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow ↗
Vertex should have a future full of bright tomorrows. 
Via The Motley Fool
News headline image
Biotech And Life Science Sector Update Summer Of 2024 ↗
It’s the slowest week of the year, we are at the market top and most earnings reports are good. 
Via Talk Markets
News headline image
Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics ↗
Jim Cramer discusses Serve Robotics, Builders FirstSource, Vertex Pharmaceuticals and Viking Therapeutics on CNBC. 
Via Benzinga
News headline image
If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,900 Today ↗
 
Via Benzinga
News headline image
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals ↗
 
Via Benzinga
News headline image
Forget Novo Nordisk: Buy This Magnificent Pharma Stock Instead ↗
Vertex Pharmaceuticals has a lot going for it. 
Via The Motley Fool
News headline image
Vertex to Participate in Upcoming September Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Biotech Bull Market: 3 Ways To Play It ↗
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally. 
Via Talk Markets
Topics Economy
News headline image
Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings ↗
Renaissance Technologies, the hedge fund founded by legendary mathematician and former NSA code breaker Jim Simons, recently disclosed its latest stock holdings in a 13F filing with the U.S. Securities... 
Via Benzinga
News headline image
These 2 Incredible Growth Stocks Are Set to Soar This Summer and Beyond ↗
It's always a good time to invest cash in quality businesses. 
Via The Motley Fool
News headline image
3 Fantastic Growth Stocks to Buy in August ↗
These stocks should keep up their winning ways. 
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
3 Biotech Stocks to Buy on the Dip: August 2024 ↗
These are three of the best biotech stocks to buy on the dip due to their strong fundamentals and market positioning. 
Via InvestorPlace
News headline image
Prediction: These 4 Future Technologies Will Be Millionaire-Makers -- and Here Are the Top Stocks to Buy Now to Profit From Them ↗
These technologies could be game-changers. And they could make forward-thinking investors a lot of money. 
Via The Motley Fool
News headline image
2 Biotech Stocks to Buy Hand Over Fist in August ↗
Both of these biotechs are highly innovative companies. 
Via The Motley Fool
News headline image
The 3 Best Biotech Stocks to Buy in August 2024 ↗
These biotech stocks are leading the way with groundbreaking therapies and robust fundamentals offering superb upside ahead. 
Via InvestorPlace
News headline image
Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England
From Vertex Pharmaceuticals
Via Business Wire
News headline image
Is It Too Late to Buy Vertex Pharmaceuticals Stock? ↗
Shares of the rare disease drugmaker are already up more than 40% over the past year. 
Via The Motley Fool
News headline image
Prediction: These Could Be the Best-Performing Growth Stocks Through 2030 ↗
Great companies are found in every type of market landscape. 
Via The Motley Fool
News headline image
3 Biotech Stocks on Track for 50% Returns (or More) by 2028 ↗
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028! 
Via InvestorPlace
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
68 69 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.